Article Text

Download PDFPDF

#243 Patterns and trends in the clinical practice of corpus uteri cancer in Belgium: an analysis of the effect database
  1. Joren Vanbraband1,
  2. Nancy Van Damme2,
  3. Geert Silversmit2,
  4. Gauthier Bouche3,
  5. Gerd Jacomen4,
  6. Eric De Jonge5,
  7. Frédéric Goffin6,
  8. Hannelore Denys7 and
  9. Frédéric Amant1,8
  1. 1KU Leuven, Leuven, Belgium
  2. 2Belgian Cancer Registry, Brussels, Belgium
  3. 3The Anticancer Fund, Meise, Belgium
  4. 4AZ Sint-Maarten, Mechelen, Belgium
  5. 5Ziekenhuis Oost-Limburg, Genk, Belgium
  6. 6CHU de Liège et Hôpital de la Citadelle, Luik, Belgium
  7. 7University Hospital Ghent, Ghent, Belgium
  8. 8Netherlands Cancer Institute, Amsterdam, The Netherlands


Introduction/Background This study aims to examine the treatment patterns and quality of care for endometrial carcinoma (EC) in Belgium, including trends in practice over time.

Methodology To study patterns and quality of care, quality indicators were developed, and the data necessary to measure these indicators was prospectively collected and stored in the EFFectiveness of Endometrial Cancer Treatment (EFFECT) database by the Belgian Cancer Registry (BCR) using an online registration module. To study trends over time, multivariable logistic mixed regression was used to estimate risk-adjusted odds ratios (aORs) and 95% confidence intervals (CIs) for associations between the quality indicators and year of diagnosis.

Results The EFFECT database covers detailed information on the care provided to 4178 patients diagnosed with corpus uteri cancer in Belgium between 2012 and 2016. First, 97.6% (n=4077) of all patients were discussed in at least one multidisciplinary team meeting, which increased from 96.4% (n=726) in 2012 to 98.5% (n=767) in 2016 (aOR=2.95; 95% CI=1.43–6.08). Second, minimally invasive (laparoscopic or robotic) surgery was used in 61.6% (n=1359) of all patients who had surgery for stage I EC, increasing from 52.9% (n=192) in 2012 to 66.4% (n=285) in 2016 (aOR=1.99; 95% CI=1.35–2.95). At least pelvic lymphadenectomy was performed in 69.0% (n=363) of all patients with stage I, high-grade (type I grade 3 or type II) EC. Third, adjuvant radiotherapy was administered to 33.5% (n=107) of all patients who received surgery (without lymph node staging) for stage I EC at high-intermediate or high risk of recurrence. Adjuvant chemotherapy was applied in 64.4% (n=270) of all patients who had surgery for locally advanced (stage III-IVA) EC.

Conclusion This study suggests that improvements are needed in both the surgical and adjuvant treatment of EC in Belgium. However, some improvements were already observed over the period 2012–2016, and clinical practice may have further advanced since.

Disclosures Funded by The Anticancer Fund and Kom op tegen Kanker.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.